The DOI matches its Crossref record.
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
Abstract
PURPOSE: A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and myelorestorative properties that could be beneficial in cancer treatment. PATIENTS AND METHODS: In this phase I trial, IL-1 alpha was administered intravenously (IV) during a 15-minute period daily for 7 days to patients with advanced solid malignancies. RESULTS: The maximum-tolerated dose (MTD) of IL-1 alpha alone was 0.3 microgram/kg. A second group of patients received indomethacin plus IL-1 alpha based on preclinical studies, which indicated that indomethacin could abrogate IL-1 alpha-induced hypotension; however, the MTD of IL-1 alpha plus indomethacin was 0.1 microgram/kg lower than IL-1 alpha alone. Fever, chills, headache, nausea, vomiting, and myalgia were common but were not dose-limiting. Hypotension resulted from a marked decrease in systemic vascular resistance and required pressors at 0.3 and 1.0 micrograms/kg IL-1 alpha. Dose-limiting toxicities included hypotension, myocardial infarction, confusion, severe abdominal pain, and renal insufficiency. IL-1 alpha treatment caused a significant, dose-related increase in the total WBC count (mainly segmented neutrophils and neutrophilic bands). Bone marrow cellularity increased because of enhanced numbers of relatively mature myeloid cells and megakaryocytes. Platelet counts decreased during therapy but were significantly elevated above baseline values 1 to 2 weeks posttreatment; this may have been an effect of IL-6 that was shown to be induced by IL-1 alpha treatment. Significant increases in triglycerides, cortisol, C-reactive protein, thyroid-stimulating hormone and decreases in cholesterol, testosterone, and protein-C were observed with treatment. CONCLUSION: We conclude that at doses of IL-1 alpha that can be given safely to cancer patients, significant, potentially beneficial hematopoietic effects occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Regulation of the Hypothalamic-Pituitary-Adrenal Axis by Cytokines: Actions and Mechanisms of Action
TURNBULL, A. V., & RIVIER, C. L. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.1 · Cited by 1,297
Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist
Dinarello, C. A. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043005 · Cited by 761
Dinarello, C. A. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00023-3 · Cited by 582
Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock
Dinarello, C. A. (1997) · Chest · doi:10.1378/chest.112.6_supplement.321s · Cited by 508
Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzymea
DINARELLO, C. A. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08307.x · Cited by 498
Metadata
- Authors
- Smith, J. W., Urba, W. J., Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., & Conlon, K. C.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-07
- Volume
- 10
- Issue
- 7
- Pages
- 1141-1152
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2227468111
- Cited by
- 162
- References
- 0
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. https://app.cochat.ai/papers/10.1200/jco.1992.10.7.1141
- The paper
- Smith, J. W., Urba, W. J., Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., & Conlon, K. C. (1992). The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.7.1141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.